Chester County News and Community Website
WILMINGTON, DE — NRx Pharmaceuticals Inc. (NASDAQ: NRXP) has secured U.S. Food and Drug Administration approval for a preservative-free injectable ketamine product, positioning the company to supply American hospitals and …
FDA Clears NRx’s Preservative-Free Ketamine Amid Drug Shortage Read More WILMINGTON, DE — NRx Pharmaceuticals Inc. (Nasdaq: NRXP) has completed commercial-scale manufacturing validation for its preservative-free injectable ketamine, positioning the company to begin supplying U.S. hospitals and clinics if the …
NRx Clears Manufacturing Hurdle for Ketamine FDA Review Read More WILMINGTON, DE — NRx Pharmaceuticals Inc. (Nasdaq: NRXP) is approaching a November 10 federal regulatory decision on its preservative-free ketamine product after the Food and Drug Administration requested only minor …
NRx Nears FDA Decision on U.S.-Made Ketamine Product Read More WILMINGTON, DE — NRx Pharmaceuticals Inc. (Nasdaq: NRXP) received a revised Nov. 10 regulatory goal date for its preservative-free ketamine application after the U.S. Food and Drug Administration reclassified a …
NRx Gets Earlier FDA Goal Date for Ketamine Application Read More WILMINGTON, DE — NRx Pharmaceuticals Inc. said its HOPE Therapeutics subsidiary will become the first interventional psychiatry network to deploy Zeta Surgical’s newly FDA-cleared robotic transcranial magnetic stimulation system, expanding …
HOPE Adds Robotic TMS System Ahead of SPARC Trial Read More WILMINGTON, DE — NRx Pharmaceuticals Inc. (Nasdaq: NRXP) moved closer to a potential 2026 launch of preservative-free ketamine after the Food and Drug Administration found no major deficiencies involving the …
NRx Advances Ketamine Bid After FDA Review Clears Drug Read More WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) said its subsidiary, HOPE Therapeutics, has begun treating patients using an artificial intelligence-guided transcranial magnetic stimulation system, a move the company says …
NRx Subsidiary Begins AI-Guided TMS Treatments in Florida Clinics Read More WILMINGTON, DE — NRx Pharmaceuticals (Nasdaq: NRXP) said the U.S. Food and Drug Administration has authorized an Expanded Access Protocol for its investigational depression treatment NRX-101, potentially allowing certain patients …
FDA Clears Expanded Access Path for NRx Depression Therapy Read More WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) moved closer to potential commercialization of its preservative-free ketamine product in the first quarter as the company scaled manufacturing, advanced multiple FDA …
NRx Pushes Toward Ketamine Launch Amid FDA Review Read More WILMINGTON, DE — NRx Pharmaceuticals (Nasdaq: NRXP) received U.S. Food and Drug Administration clearance to begin a late-stage clinical trial evaluating whether its investigational NRX-101 therapy can improve outcomes for …
NRx Advances Depression Drug Study Targeting Military Use Read More